Fortis Healthcare Q4 FY25: Revenue up 12%, profit slips

Fortis Healthcare reported double-digit revenue growth in the March 2025 quarter, led by its hospital and diagnostics businesses, but the headline profit number fell year-on-year due to higher costs and impairment-led exceptional items. In Q4 FY25, the company’s consolidated revenue from operations rose 12.4% to INR 2,007 crore from INR 1,786 crore a year earlier. Consolidated net profit for the quarter declined 7.4% to INR 188.02 crore, down from INR 203.14 crore in Q4 FY24. The company attributed the profit decline mainly to higher expenses and impairments on investments and assets. Even with these pressures, Fortis reported margin expansion at the operating level and higher profit before tax.

Key Q4 FY25 numbers at a glance

The March quarter reflected a mixed outcome, with growth in core revenue and operating profitability, but a weaker reported profit after tax due to exceptional losses. Total expenses in Q4 FY25 rose 13.6% year-on-year to INR 1,741.52 crore from INR 1,531.76 crore. Fortis also booked an exceptional loss of INR 53.57 crore in the quarter. The company said this was linked to impairments on its investment in an associate firm and on some assets, including property, plant and equipment. Profit before tax (PBT) rose 8.2% year-on-year to INR 290 crore from INR 268 crore.

Why net profit fell despite revenue growth

The central driver of the year-on-year decline in Q4 net profit was cost growth that outpaced revenue growth, along with impairments reflected in exceptional items. While revenue rose 12.4%, total expenses climbed 13.6%, compressing the room for net profit expansion. In addition, the quarter included the INR 53.57 crore exceptional loss due to impairments. These factors outweighed the benefits of stronger hospital volumes, higher realisations per occupied bed, and improved operating margins. Fortis also referred to impairments in investments as a pressure point for the quarter’s reported profit.

Hospitals and diagnostics: where growth came from

Fortis said the top-line increase was driven by strong performance in both its hospital and diagnostics segments, though the growth rates differed sharply. The hospital segment reported 14.2% year-on-year revenue growth in Q4 FY25, supported by improved occupancy and better pricing and case mix. In contrast, the diagnostics business showed subdued momentum, with revenue rising 3.5% year-on-year to INR 306 crore. This difference matters because the hospital business is the company’s main engine in both revenue and operating profit contribution. Management commentary also noted that the hospital business contributed approximately 84% to consolidated revenue and consolidated EBITDA.

Operating metrics: ARPOB, occupancy, and specialty mix

Operational metrics in the hospital business moved higher in Q4 FY25, pointing to stronger underlying demand and improved monetisation. Average revenue per occupied bed (ARPOB) increased 8.4% year-on-year to INR 2.51 crore. Hospital occupancy improved to 69% from 66% in Q4 FY24. Fortis also reported strong growth in key specialties, with oncology revenue up 25% and neurosciences up 19% year-on-year in the quarter. International patient revenue rose 17% year-on-year to INR 145 crore, contributing 8.1% of overall hospital revenue, up from 7.9% in the year-ago quarter.

EBITDA growth and margin improvement

Even as net profit declined, Fortis reported a better operating performance in Q4 FY25. Consolidated EBITDA rose 14.3% year-on-year to INR 435 crore. The EBITDA margin improved to 21.7% from 21.3% in Q4 FY24. Fortis also noted an improvement in operating profit margin (OPM) to 19.45% from 16.91% in the comparable quarter last year. Management commentary for FY25 indicated that hospital business operating EBITDA margins improved from 18.6% to 20.5%, with hospital business EBITDA of INR 1,339 crore.

Exceptional items: Q3 gains vs Q4 losses

Fortis’ quarterly results also show how exceptional items can change reported profits. In the December quarter, Fortis reported an 89% jump in consolidated net profit to INR 254.3 crore, supported by exceptional gains. The company disclosed an exceptional item gain of INR 23.5 crore from the sale of Richmond Road Hospital, Bengaluru, and INR 0.30 crore from reversal of an allowance related to interest accrued receivable from Fortis C Doc Healthcare Ltd. In Q4 FY25, the picture reversed with an exceptional loss of INR 53.57 crore related to impairments. This sequence helps explain why operating indicators improved even as reported Q4 net profit fell.

Full-year FY25 snapshot and balance sheet position

For FY25, Fortis reported consolidated revenue from operations of INR 7,782.75 crore, up from INR 6,892.92 crore in FY24. Consolidated net profit for FY25 stood at INR 809.38 crore compared with INR 645.22 crore in FY24. Fortis also reported profit after tax before exceptional items for the year increased 42.8% to INR 899 crore. On the balance sheet, the company’s net debt as of 31 March stood at INR 1,694 crore, with net debt to EBITDA at 0.93x.

Dividend and near-term operating plan

Fortis announced a final dividend of INR 1.00 per share. On execution priorities, the company said it aims to improve margins by FY26 by maintaining high occupancy, increasing complex procedures, and adding 800 new beds during the year. These operational levers typically influence ARPOB, occupancy, and mix, which were already moving in a positive direction in Q4 FY25. The pace of bed additions and the ability to sustain utilisation will be key operational watch points.

Summary table: key reported financial and operating data

Market impact: what investors typically track from these numbers

For investors, the quarter highlights a common trade-off in hospital businesses: growth in revenue and operating margins can coexist with weaker reported profit when impairments and expenses rise. The strong revenue growth, higher ARPOB, and better occupancy are supportive indicators of core demand. At the same time, the increase in expenses and the exceptional loss show that reported earnings can swing due to one-off items and accounting adjustments. The net debt of INR 1,694 crore and net debt-to-EBITDA of 0.93x provide a reference point for balance-sheet leverage as Fortis pursues bed additions.

Conclusion

Fortis Healthcare closed Q4 FY25 with 12.4% revenue growth to INR 2,007 crore, improved EBITDA and margins, and better operating metrics such as ARPOB and occupancy. Reported net profit fell to INR 188.02 crore due to higher expenses and a INR 53.57 crore exceptional loss linked to impairments. The company has announced a final dividend of INR 1.00 per share and outlined steps to improve margins by FY26, including adding 800 beds and increasing complex procedures. The next set of results will help investors judge whether operating momentum continues while exceptional and cost pressures stabilise.